<code id='A046FF2DED'></code><style id='A046FF2DED'></style>
      • <acronym id='A046FF2DED'></acronym>
      <center id='A046FF2DED'><center id='A046FF2DED'><tfoot id='A046FF2DED'></tfoot></center><abbr id='A046FF2DED'><dir id='A046FF2DED'><tfoot id='A046FF2DED'></tfoot><noframes id='A046FF2DED'>
      • <optgroup id='A046FF2DED'><strike id='A046FF2DED'><sup id='A046FF2DED'></sup></strike><code id='A046FF2DED'></code></optgroup>
        5. <b id='A046FF2DED'><label id='A046FF2DED'><select id='A046FF2DED'><dt id='A046FF2DED'><span id='A046FF2DED'></span></dt></select></label></b><u id='A046FF2DED'></u>
          <i id='A046FF2DED'><strike id='A046FF2DED'><tt id='A046FF2DED'><pre id='A046FF2DED'></pre></tt></strike></i>
           


   

   

   
   
   
   
   
   
   
   
   
   
   
   
   

   
   
   
   
   
   
   
  
           
  
           
  
           
   
           
    
           
     
           
      
           
       
      
           
      
           
       
           
        
           
         
           
           
          
           
         
           
         
           
           
          
           
         
           
          
        
           
       
           
       
           
        
           
        
           
        
           
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
       
           
       
           
        
           
        
          
          00:00 
        
           
       
           
       
           
      
           
      
           
        
        
        
       
           
        00:00 
         
        00:00 
        LIVE 
       
           
        
       
           
        
           
        
           
        
           
        
           
       
           
       
           
       
           
        
        
        
        
        
        
        
        
        
      
           
       
    
    
      
           
       
           
      
           
     
           
     
           
       
     
           
     
           
      
           
      
           
      
           
      
           
       
           
      
           
      
           
      
           
       
           
       
          
         buffering 
       
           
      
           
      
           
       
           
        
           
        
          
          Replay 
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
        
           
        
           
        
           
       
           
      
           
      
           
      
           
      
           
      
           
       
           
      
           
     
           
     
           
      
           
     
           
     
           
      
           
       
           
        
           
       
           
       
           
        
          
          LIVE 
        
           
        00:00 
         /  
        00:00 
       
           
       
           
        
           
        
           
        
           
         
           
         
           
         
           
         
           
         
           
         
           
        
           
        
           
        
           
       
           
       
           
        
           
        
          
          LIVE 
        
           
       
           
       
           
        
           
        
          
          CC 
        
           
       
           
       
           
        
           
       
           
       
           
       
           
        
           
        
           
         
           
        
           
       
           
       
           
        
           
       
           
      
           
      
           
       
           
        
           
        
           
         
           
         
           
         
           
          
           
          
           
          
           
         
           
        
           
       
           
      
           
      
           
       
           
     
       
           
    
       
           
       
    
  
       
           
   
       
           
       
       
           
      
           
      
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       Opacity : 
        
      
           
     
           
     
           
     
           
      
           
  
     
           
    
           
    
           
    
           
     
          
       Share: 
     
           
      
     
           
      
      Copy 
     
           
      
    
           
    
          
      Close 
      
    
           
    
           
      
    
           
    
           
   
           
  
           
  
           
    
    
    
   
           
   
           
 
    
   
           
   
           
   
           
    
           
     
           
      
           
       
           
        
           
          
          
         
          
          Wikipedia 

          
          
            
          
          

           
           
        
           
       
           
      
           
     
           
    
           
    
           
     
           
      
           
      
           

                       
          knowledge  
          
                                   
                 
                                      author：fashion   
                                        
                                      
                                      -
 
browse：98
                                  
                                    
          
                                    
            
          
 
          AP/Business Wire
          There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.
          But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.
          advertisement
          That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.
          STAT+ Exclusive Story
          Already have an account? Log in
          STAT+
          This article is exclusive to STAT+ subscribers
          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
          Already have an account? Log in
          Already have an account? Log in
          Monthly
          $39
          Totals $468 per year
          $39/month			Get Started			
          Totals $468 per year
          Starter
          $30
          for 3 months, then $39/month
          $30 for 3 months			Get Started			
          Then $39/month
          Annual
          $399
          Save 15%
          $399/year			Get Started			
          Save 15%
          11+ Users
          Custom
          Savings start at 25%!
          Request A Quote			Request A Quote			
          Savings start at 25%!
          2-10 Users
          $300
          Annually per user
          $300/year			Get Started			
          $300 Annually per user
          View All Plans																															
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
           
 
 
          

                              
          
                                 Previous article：

                                
                                          Medical records are filled with copy
                                
                            
          Next article：  
                                      
                                          US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage
                                                                    
          

      
           
      
           
        
           
                                               
        
           Wikipedia 
           
                   
      
           
  
  
          
    
          
        
          
            
          
                                                     
                
          knowledge
          
                            
          
        
          
        
    
          

          

    

      
           
     
           


   
    
           
   
           
  
 

  
           
    
           
           
           
            
            Back To Top 
           
           
           
           

            
           
                                                                    
                 
          knowledge
           
                                      
            
           
          
           
                                                          
             
          hotspot
           
                             
            
           
            
           

                                                         
             
          knowledge
           
               
              
            
           
            
           
                                                         
             
          hotspot
           
                             
      
           
 
     
           
     
           
      
          
              PabloMartinezMonsivais/APYou’rereadingthewebeditionofHealthCareInc.,STAT’sweeklynewsletterfollowingt
             
           
      
          
        © 2013-2023.Company name All rights reserved.Site Map 
         WSS-More Templates  
             Guangdong ICP952name